{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:22:02Z","timestamp":1793967722054,"version":"4.8.0"},"reference-count":18,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We investigated the role of Nek2, a member of the serine\/threonine kinase family, Nek, in the tumorigenic growth of cholangiocarcinoma cells. Expression of Nek2 is elevated in cholangiocarcinoma in a tumor-specific manner as compared with that of normal fibroblast cells. Expression of exogenous Nek2 did not perturb the growth of cholangiocarcinoma cells, whereas suppression of the Nek2 expression with siRNA resulted in the inhibition of cell proliferation and induced cell death. In xenograft-nude mouse model, s.c. injection of Nek2 siRNA around the tumor nodules resulted in reduction of tumor size as compared with those of control siRNA injection. In peritoneal dissemination model, Nek2 siRNA\u2013treated mice showed statistically longer survival periods in comparison with those of the control siRNA\u2013treated mice. Taken together, our data indicate a pivotal role of Nek2 in tumorigenic growth of cholangiocarcinoma. [Cancer Res 2007;67(20):9637\u201342]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1489","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T17:39:01Z","timestamp":1192642741000},"page":"9637-9642","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma"],"prefix":"10.1158","volume":"67","author":[{"given":"Toshio","family":"Kokuryo","sequence":"first","affiliation":[{"name":"1Surgical Oncology and Divisions of"},{"name":"2Cancer Biology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Senga","sequence":"additional","affiliation":[{"name":"2Cancer Biology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"1Surgical Oncology and Divisions of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nagino","sequence":"additional","affiliation":[{"name":"1Surgical Oncology and Divisions of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nimura","sequence":"additional","affiliation":[{"name":"1Surgical Oncology and Divisions of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinari","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"2Cancer Biology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"2022061623215964900_B1","doi-asserted-by":"crossref","unstructured":"Nimura Y, Kamiya J, Nagino M, et al. Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg\u20081998; 5: 52\u201361.","DOI":"10.1007\/PL00009951"},{"key":"2022061623215964900_B2","doi-asserted-by":"crossref","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov\u20082002; 1: 493\u2013502.","DOI":"10.1038\/nrd839"},{"key":"2022061623215964900_B3","doi-asserted-by":"crossref","unstructured":"Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J\u20081998; 17: 470\u2013481.","DOI":"10.1093\/emboj\/17.2.470"},{"key":"2022061623215964900_B4","doi-asserted-by":"crossref","unstructured":"Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene\u20082002; 21: 6184\u201394.","DOI":"10.1038\/sj.onc.1205711"},{"key":"2022061623215964900_B5","doi-asserted-by":"crossref","unstructured":"Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y. One hundred consecutive hepatobiliary resections for biliary hilar malignancy: preoperative blood donation, blood loss, transfusion, and outcome. Surgery\u20082005; 137: 148\u201355.","DOI":"10.1016\/j.surg.2004.06.006"},{"key":"2022061623215964900_B6","doi-asserted-by":"crossref","unstructured":"Kokuryo T, Yamamoto T, Oda K, et al. Profiling of gene expression associated with hepatolithiasis by complementary DNA expression array. Int J Oncol\u20082003; 22: 175\u20139.","DOI":"10.3892\/ijo.22.1.175"},{"key":"2022061623215964900_B7","doi-asserted-by":"crossref","unstructured":"Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ, Muschel RJ. Inhibition of centrosome separation after DNA damage: a role for Nek2. Radiat Res\u20082004; 162: 128\u201335.","DOI":"10.1667\/RR3211"},{"key":"2022061623215964900_B8","doi-asserted-by":"crossref","unstructured":"Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res\u20082004; 64: 7370\u20136.","DOI":"10.1158\/0008-5472.CAN-04-0960"},{"key":"2022061623215964900_B9","doi-asserted-by":"crossref","unstructured":"Prigent C, Glover DM, Giet R. Drosophila Nek2 protein kinase knockdown leads to centrosome maturation defects while overexpression causes centrosome fragmentation and cytokinesis failure. Exp Cell Res\u20082005; 303: 1\u201313.","DOI":"10.1016\/j.yexcr.2004.04.052"},{"key":"2022061623215964900_B10","doi-asserted-by":"crossref","unstructured":"Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett\u20082006; 237: 155\u201366.","DOI":"10.1016\/j.canlet.2005.06.017"},{"key":"2022061623215964900_B11","doi-asserted-by":"crossref","unstructured":"Machida K, Matsuda S, Yamaki K, et al. v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells. Oncogene\u20082000; 19: 1710\u20138.","DOI":"10.1038\/sj.onc.1203497"},{"key":"2022061623215964900_B12","doi-asserted-by":"crossref","unstructured":"Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J\u20081993; 12: 307\u201314.","DOI":"10.1002\/j.1460-2075.1993.tb05658.x"},{"key":"2022061623215964900_B13","doi-asserted-by":"crossref","unstructured":"Mon NN, Ito S, Senga T, Hamaguchi M. FAK signaling in neoplastic disorders: a linkage between inflammation and cancer. Ann N Y Acad Sci\u20082006; 1086: 199\u2013212.","DOI":"10.1196\/annals.1377.019"},{"key":"2022061623215964900_B14","doi-asserted-by":"crossref","unstructured":"Fardilha M, Wu W, Sa R, et al. Alternatively spliced protein variants as potential therapeutic targets for male infertility and contraception. Ann N Y Acad Sci\u20082004; 1030: 468\u201378.","DOI":"10.1196\/annals.1329.059"},{"key":"2022061623215964900_B15","doi-asserted-by":"crossref","unstructured":"Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg\u20082002; 235: 392\u20139.","DOI":"10.1097\/00000658-200203000-00011"},{"key":"2022061623215964900_B16","doi-asserted-by":"crossref","unstructured":"Weinstein IB. Addiction to oncogenes\u2014the Achilles heal of cancer. Science\u20082002; 297: 63\u20134.","DOI":"10.1126\/science.1073096"},{"key":"2022061623215964900_B17","doi-asserted-by":"crossref","unstructured":"Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res\u20082004; 64: 3365\u201370.","DOI":"10.1158\/0008-5472.CAN-03-2682"},{"key":"2022061623215964900_B18","doi-asserted-by":"crossref","unstructured":"Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol\u20082004; 22: 1579\u201382.","DOI":"10.1038\/nbt1038"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9637\/2575359\/9637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9637\/2575359\/9637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:00:40Z","timestamp":1655420440000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/20\/9637\/533708\/Nek2-as-an-Effective-Target-for-Inhibition-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":18,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2007,10,17]]},"published-print":{"date-parts":[[2007,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1489","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}